Fasudil hydrochloride:Exports & Compliance White Paper 2026

I. Executive Summary

Fasudil hydrochloride, CAS 105628-07-7, is the hydrochloride salt of fasudil, chemically 1-(5-isoquinolinesulfonyl)homopiperazine, a small-molecule inhibitor of Rho-associated coiled-coil kinase (ROCK). The salt is used because it delivers the aqueous solubility required for injectable presentation. Fasudil is a prescription medicine in a limited number of markets, having been introduced in Japan and subsequently in China for the management of cerebral vasospasm following subarachnoid haemorrhage, while remaining unapproved as a marketed drug in the United States and the European Union.

This paper is written from the API export-compliance standpoint. The material is an active pharmaceutical ingredient intended for licensed pharmaceutical manufacturers and authorized distribution channels, not for direct handling by patients or by unlicensed intermediaries. Its commercial value therefore rests less on unit price than on the completeness of the regulatory file behind it: manufacture to ICH Q7 good manufacturing practice, an active-substance master file or certificate of suitability, a mutagenic-impurity assessment covering sulfonyl halide chemistry, and a defensible nitrosamine risk assessment covering the secondary-amine homopiperazine moiety.

Buyers are generic formulators, hospital-injectable manufacturers, national tender procurers and clinical-stage sponsors developing other Rho-kinase inhibitors. The guidance that follows addresses route chemistry, specification design, dossier strategy and logistics for professional procurement and regulatory audiences. It does not provide, and must not be read as providing, any advice on self-medication: fasudil hydrochloride is a prescription-only active substance whose use is determined solely by a qualified prescriber under national law.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Fasudil is an isoquinoline-5-sulfonamide bearing a homopiperazine (1,4-diazepane) ring; the sulfonamide nitrogen and the two ring nitrogens give the molecule a distinctly basic character, which is why the hydrochloride salt is used for parenteral presentation. The salt is freely soluble in water and hygroscopic in the solid state; hydrate, anhydrate and polymorphic behaviour must be controlled explicitly because they affect assay, dissolution and stability.

• Mechanism — Rho-kinase inhibition: Fasudil inhibits Rho-associated kinase, suppressing Rho-mediated calcium sensitisation and myosin light-chain phosphorylation in vascular smooth muscle, producing vasodilation without the calcium-channel or nitric-oxide dependency of classical vasodilators. The mechanism underlies both its approved cerebrovascular use and ongoing investigation in pulmonary hypertension, ocular disease and fibrosis.
• Solid-form and solution behaviour: Because the API is hygroscopic, water content is a specification-critical attribute with direct consequences for assay correction and for stability. Aqueous solutions are sensitive to pH and to light, and injectable manufacture accordingly controls pH, oxygen headspace and terminal sterilization or aseptic processing. For solid-state release, XRPD is used to fix the crystalline form lot-to-lot.

2.2 Synthesis and Manufacturing Technologies

The industrial route class is short and well established: electrophilic sulfonation of isoquinoline to the 5-sulfonic acid, conversion to the corresponding sulfonyl chloride, sulfonamide formation with homopiperazine, and isolation as the hydrochloride salt. Each step carries a distinct control burden — regioselectivity in sulfonation, genotoxic potential in the acid chloride, bis-sulfonylation in the coupling, and solid-form control in the salt formation — which is where process development effort is concentrated.

• Sulfonation, chlorination and genotoxic control: Sulfonation with oleum or fuming sulfuric acid must be run to control the 5-isomer against sulfonation at other ring positions, with the crude sulfonic acid converted to isoquinoline-5-sulfonyl chloride by chlorinating agents. Sulfonyl halides are reactive, moisture-sensitive and carry a structural alert for mutagenicity, so they are controlled as process impurities under ICH M7 with a compound-specific acceptable intake rather than treated as ordinary related substances.
• Sulfonamide coupling, salt formation and injectable-grade finishing: Coupling of the sulfonyl chloride with homopiperazine is run under Schotten–Baumann-type conditions with controlled stoichiometry and addition order to suppress the bis-sulfonylated diamine, the single most characteristic related substance of this API. The hydrochloride is then crystallized under a defined solvent and cooling profile to fix the solid form, and injectable-grade material additionally requires bioburden and bacterial-endotoxin control, particulate-matter assessment and, where applicable, sterile crystallization or terminal sterilization.

2.3 Core Application Matrix

• API for authorized injectable medicines: The dominant commercial outlet is supply to licensed manufacturers of fasudil hydrochloride injection in markets where the product is approved, including Japan and China. Requirements include a registered specification, stability data generated under ICH Q1A conditions, and a dossier — DMF, ASMF or national registration — that the finished-product marketing-authorization holder can reference.
• Clinical supply for other Rho-kinase programmes: Sponsors investigating ROCK inhibition in pulmonary arterial hypertension, glaucoma, fibrosis, spinal-cord injury and cardiovascular indications require GMP campaign material with full traceability, validated methods and, where parenteral dosing is planned, endotoxin-controlled API.
• Reference and impurity standards for quality control: Quality-control laboratories purchase primary reference standards and characterized impurity standards — including the bis-sulfonylated adduct, des-sulfonylated species and regioisomeric sulfonamides — for assay calibration and method validation in finished-product release testing.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand for the API tracks three forces. First, population ageing and the persistent incidence of aneurysmal subarachnoid haemorrhage sustain hospital demand for cerebral vasospasm therapy in the markets where the product is registered, . Second, hospital procurement in China operates largely through volume-based tendering, which compresses API margins while increasing volume predictability. Third, fasudil remains one of the most widely used tool inhibitors of Rho kinase in academic and industrial pharmacology, generating steady demand for research-grade material that is deliberately kept separate from GMP supply.

3.2 Capacity Distribution and Export Flows

Commercial API capacity is concentrated in East and South Asia. Chinese producers in Zhejiang, Jiangsu and Shandong combine sulfonation, chlorination and sulfonamide coupling in multipurpose GMP plants and supply both domestic formulators and export customers; Japanese manufacture is associated with the originator and with high-specification domestic supply; Indian producers increasingly target export through DMF- and WHO-GMP-aligned facilities. Export flows follow finished-product registration: material moves to the jurisdiction of the marketing-authorization holder, with documentation — not freight — determining whether a shipment clears.

3.3 Market Bifurcation and Pricing Dynamics

The market is bifurcated between dossier-backed GMP API and undifferentiated material. Only the former can be referenced by a regulated marketing-authorization holder; Price within the GMP segment is set by five attributes: availability of an open DMF, ASMF or CEP, the injectable-grade package (endotoxin, bioburden, particulate matter, sterility where applicable), particle-size specification, residual-solvent results, and the nitrosamine and M7 assessments. Tender-driven generic competition transfers price pressure upstream, so suppliers differentiate on dossier readiness and change-control reliability rather than on discounting.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Fasudil hydrochloride sits inside the most heavily regulated category in chemical trade: an active substance that may only be incorporated into a finished medicine by licensed manufacturers under a valid marketing authorization. Export is therefore documentation-led. The API manufacturer must be able to demonstrate ICH Q7 compliance, maintain a dossier that the finished-product applicant can cross-reference, and operate distribution under good distribution practice with full batch traceability and recall capability.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH, CLP and the medicinal-products interface: Registration position must be assessed on total manufactured or imported tonnage, distinguishing quantities placed in authorised medicinal products from any non-medicinal use, and importers should confirm their position with ECHA rather than assume an exemption.
• ASMF, CEP and the written-confirmation requirement: European market access is normally built on an active substance master file submitted to national authorities or on a Certificate of Suitability from the EDQM. Imported API is additionally subject to the written-confirmation requirement for active substances manufactured outside the EU, under which the exporting country's competent authority must confirm GMP equivalence, unless the exporting country benefits from an equivalence decision. Practical consequence: a supplier without these instruments is effectively locked out of regulated EU tenders.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA drug-master-file and cGMP framework: US supply is routed through a Type II drug master file that the finished-dose applicant references in its application, supported by ICH Q7 cGMP compliance, establishment registration and listing, and readiness for pre-approval inspection. Because fasudil is not an FDA-approved drug in most presentations, US demand is dominated by investigational and research channels, which still require the sponsor's regulatory pathway — an IND or an approved application — before human use.
• TSCA scope and environmental permitting: Chemical inventory obligations under TSCA generally do not attach to substances regulated as drugs by FDA, but intermediates, research quantities and non-pharmaceutical uses may fall within scope, so exporters should confirm the basis for each shipment. Environmental permitting is the more immediate constraint: sulfonation and chlorination generate acidic and phosphorus-containing waste streams that must be permitted and treated, .

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Sulfonation and chlorination chemistry carries a heavier environmental footprint than the molecule's small size suggests, and European and Japanese customers increasingly audit it directly. Waste acid, sulfur dioxide and phosphorus-containing effluents dominate Scope 1 impacts, while solvent use and purchased reagents drive Scope 3. Suppliers who can document abatement are measurably easier to qualify.

5.1 Carbon Footprint and Circular Economy

Priority measures are recovery and reconcentration of spent sulfuric acid, scrubbing of acidic off-gas, conversion of phosphorus-containing residues into recoverable phosphate streams rather than landfill, and solvent recovery by distillation for the coupling and crystallization steps. Energy efficiency hinges on the crystallization and drying stages, which are lengthy for a hygroscopic salt. Buyers should request a campaign mass balance and wastewater characterisation.

5.2 Sustainable Sourcing and Traceability

Traceability must extend from the API batch back through the sulfonyl chloride intermediate to the isoquinoline and homopiperazine sources, with named subcontractors and documented change control. Because the finished product is injectable, customers expect ISO 9001 or ISO 14001 certification, evidence of GMP inspection history, and a written statement of the nitrosamine control strategy across the supply chain. Undisclosed subcontracting of the chlorination step is the most common cause of divergent impurity profiles between qualification and commercial batches.

VI. Supply Chain Resilience and Export Logistics

The API is hygroscopic and light-sensitive, so logistics are governed by moisture and light control rather than by hazard class. Consignments move under good distribution practice with documented temperature and humidity conditions, sealed tamper-evident packaging and batch-level documentation that allows recall.

6.1 Packaging Standards and Moisture/Contamination Control

• Primary containment: Double polyethylene bags with desiccant inside fibre or HDPE drums, or aluminium-foil laminate pouches for smaller packs, with headspace managed to limit moisture ingress. Light protection is achieved by opaque outer packaging, and each drum carries a tamper-evident seal with batch, retest date and storage statement — typically controlled room temperature with protection from moisture.
• Documentation and identity controls: Every shipment should be accompanied by a certificate of analysis referencing the registered specification, a GMP statement or equivalent, and transport documentation sufficient for customs and for the importing marketing-authorization holder's goods-receipt procedure. Where a cold-chain condition is claimed, data-logger records must accompany the batch and exceed the documented storage range only under a formal deviation assessment.

6.2 Dangerous Goods Identification and Transit Protocols

Fasudil hydrochloride is generally not assigned a dangerous-goods classification for transport, but the shipper must confirm that position against the current safety data sheet and the applicable dangerous-goods list rather than assume it, . In practice, API moves by air freight for high-value low-volume consignments and by sea freight for commercial quantities, declared under the heterocyclic-compound heading of the harmonized system, with a customs broker competent in pharmaceutical entries. Buyers should specify humidity-indicating cards and logger-verified transit, since condensation inside a drum is the commonest cause of water-content failure on receipt.

VII. Enterprise Global Expansion Strategy Guide

Export success for this API is a function of dossier coverage and quality-system credibility rather than of price leadership. The priorities below follow the sequence in which regulated customers qualify a new source.

1. Build multi-jurisdiction dossier coverage: Maintain an open US DMF Type II, an EU ASMF or EDQM CEP, and a national registration for Asian markets, keeping the open and restricted parts aligned so that customer questions are answered from one controlled source.
2. Differentiate on injectable-grade quality: Invest in bacterial-endotoxin and bioburden capability, particulate-matter assessment, particle-size control and, where customers require it, sterile crystallization. Pair this with a documented nitrosamine risk assessment and an ICH M7 position for sulfonyl halide residues; these two assessments are now routinely requested at supplier qualification and their absence stalls approval.
3. Operate a licensed-channel commercial model: Sell only through verified, licensed pharmaceutical customers with documented end-use, maintain GDP-compliant distribution with batch traceability and recall readiness, and offer dual-site or buffer-stock arrangements that protect tender commitments.

VIII. Conclusion

Fasudil hydrochloride occupies a mature but geographically narrow API market whose entry barriers are documentary rather than chemical. The route is well understood and the molecule is not novel; what separates a sellable API from an unsellable one is whether the batch arrives with an ICH Q7 pedigree, a referenceable dossier, a nitrosamine and M7 position, and an injectable-grade control package. Suppliers who invest in those four assets can compete in regulated markets despite generic price pressure;

For buyers, the qualification checklist is stable: verify the dossier instrument available for your market, audit or obtain third-party evidence of GMP status and inspection history, require the nitrosamine and genotoxic-impurity assessments before ordering, and confirm moisture-protective packaging with logger-verified transit. Above all, treat the material for what it is — a prescription-only active substance for licensed pharmaceutical manufacture. That boundary is not a formality; it is the condition that keeps the supply chain legal, auditable and safe.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Fasudil hydrochloride Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Fasudil hydrochloride supply chain:

• China — sulfonation and chlorination capacity at scale: Zhejiang, Jiangsu and Shandong producers combine oleum sulfonation, sulfonyl-chloride generation and sulfonamide coupling in multipurpose GMP plants serving domestic tender demand and export customers. Registration on the national excipient and raw-material platform has made Chinese sites the default source for cost-competitive commercial volumes.
• Japan — originator standards and specification leadership: Japan is where fasudil was developed and first marketed, and its ecosystem retains the reference specifications and impurity knowledge that define a compliant batch.
• India — dossier-driven export capability: Hyderabad, Visakhapatnam and Gujarat API manufacturers pair WHO-GMP and US-facing facilities with strong regulatory-writing teams, producing US DMF and EU ASMF filings efficiently. Indian suppliers are selected where dossier turnaround and multi-market filing coverage are the buyer's priority.